Stockreport

Contineum falls after missing main goals in multiple sclerosis trial [Seeking Alpha]

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF The trial did not achieve its main goals for effectiveness. There was no notable improvement in patients' binocular 2.5% low contrast letter acuity across the different [Read more]